ATE359069T1 - Therapeutische zusammenstellungen - Google Patents
Therapeutische zusammenstellungenInfo
- Publication number
- ATE359069T1 ATE359069T1 AT99946906T AT99946906T ATE359069T1 AT E359069 T1 ATE359069 T1 AT E359069T1 AT 99946906 T AT99946906 T AT 99946906T AT 99946906 T AT99946906 T AT 99946906T AT E359069 T1 ATE359069 T1 AT E359069T1
- Authority
- AT
- Austria
- Prior art keywords
- patient
- physiologically acceptable
- therapeutic compositions
- acceptable ketosis
- ketosis
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 208000007976 Ketosis Diseases 0.000 abstract 2
- 230000004140 ketosis Effects 0.000 abstract 2
- WHBMMWSBFZVSSR-GSVOUGTGSA-M (R)-3-hydroxybutyrate Chemical compound C[C@@H](O)CC([O-])=O WHBMMWSBFZVSSR-GSVOUGTGSA-M 0.000 abstract 1
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 230000036765 blood level Effects 0.000 abstract 1
- 150000001768 cations Chemical class 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 201000010901 lateral sclerosis Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000005264 motor neuron disease Diseases 0.000 abstract 1
- 150000003254 radicals Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D323/00—Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Polyesters Or Polycarbonates (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10037198P | 1998-09-15 | 1998-09-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE359069T1 true ATE359069T1 (de) | 2007-05-15 |
Family
ID=22279402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99946906T ATE359069T1 (de) | 1998-09-15 | 1999-09-15 | Therapeutische zusammenstellungen |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20010014696A1 (de) |
| EP (1) | EP1123094B1 (de) |
| JP (1) | JP2002524506A (de) |
| KR (1) | KR100805490B1 (de) |
| CN (1) | CN1273129C (de) |
| AT (1) | ATE359069T1 (de) |
| AU (1) | AU767238B2 (de) |
| BR (1) | BR9913680A (de) |
| CA (1) | CA2339941A1 (de) |
| DE (1) | DE69935799T2 (de) |
| DK (1) | DK1123094T3 (de) |
| ES (1) | ES2283133T3 (de) |
| NZ (1) | NZ509739A (de) |
| PT (1) | PT1123094E (de) |
| RU (1) | RU2242227C2 (de) |
| WO (1) | WO2000015216A1 (de) |
| ZA (1) | ZA200101260B (de) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2752800T3 (es) * | 2000-05-01 | 2020-04-06 | Cerecin Inc | Uso de triglicéridos de cadena media para el tratamiento y la prevención de la enfermedad del Parkinson resultante de un metabolismo neuronal reducido |
| US6835750B1 (en) | 2000-05-01 | 2004-12-28 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II |
| US8124589B2 (en) | 2000-05-01 | 2012-02-28 | Accera, Inc. | Use of ketogenic compounds for treatment of age-associated memory impairment |
| DK1648952T3 (en) | 2003-06-03 | 2018-05-28 | The Us Gov As Represented By The Department Of Health And Human Services | Dietary supplements and therapeutic compositions comprising (R) -3-hydroxybutyrate derivatives |
| CN1972698B (zh) * | 2003-09-01 | 2010-06-02 | 有限会社爱泽世 | β-羟基短-中链脂肪酸聚合物 |
| US7132221B2 (en) * | 2003-09-12 | 2006-11-07 | Headway Technologies, Inc. | Method to print photoresist lines with negative sidewalls |
| GB0410266D0 (en) * | 2004-05-07 | 2004-06-09 | Ketocytonyx Inc | Treatment of apoptosis |
| GB0420856D0 (en) * | 2004-09-20 | 2004-10-20 | Ketocytonyx Inc | Cns modulators |
| EP1778615A4 (de) | 2004-07-20 | 2010-01-06 | Btg Int Ltd | Oligomere ketonverbindungen |
| WO2006034361A2 (en) * | 2004-09-21 | 2006-03-30 | Ketocytonyx Inc. | Dopaminergic mimetics |
| GB0427145D0 (en) * | 2004-12-10 | 2005-01-12 | Ketocytonyx Inc | Compositions for use in surgery |
| WO2007001883A2 (en) | 2005-06-20 | 2007-01-04 | Accera, Inc. | Method to reduce oxidative damage and improve mitochondrial efficiency |
| RU2317304C1 (ru) * | 2006-04-17 | 2008-02-20 | Институт химической биологии и фундаментальной медицины Сибирского отделения Российской академии наук (СО РАН) | Пептид, обладающий апоптотической активностью по отношению к раковым клеткам человека |
| WO2008005818A1 (en) * | 2006-06-30 | 2008-01-10 | Stepan Co | Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose |
| US20080089981A1 (en) * | 2006-10-17 | 2008-04-17 | N.V. Nutricia | Ketogenic diet |
| EP2143434A4 (de) | 2007-03-30 | 2014-07-23 | Earthus Inc | Zusammensetzung zur förderung der bildung von ketonverbindungen |
| CA2684213A1 (en) | 2007-04-12 | 2008-10-23 | Regents Of The University Of Minnesota | Ischemia/reperfusion protection compositions and methods of using |
| CN101293831B (zh) * | 2007-04-27 | 2013-09-18 | 汕头大学 | 3-羟基脂肪酸及其衍生物在制备钙离子通道调节剂中的用途 |
| EP2179284B1 (de) | 2007-07-31 | 2016-09-28 | Accera, Inc. | Verwendung genomischer und ketogener verbindungen zur behandlung von beeinträchtigten kognitiven funktionen |
| ES2748136T3 (es) | 2007-10-15 | 2020-03-13 | United Animal Health Inc | Método para aumentar el rendimiento de las crías |
| WO2009089144A1 (en) * | 2008-01-04 | 2009-07-16 | Isis Innovation Limited | Ketone bodies and ketone body esters as blood lipid lowering agents |
| US8105809B2 (en) | 2008-07-03 | 2012-01-31 | Accera, Inc. | Enzymatic synthesis of acetoacetate esters and derivatives |
| US9125881B2 (en) | 2008-07-03 | 2015-09-08 | Accera, Inc. | Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders |
| US8642654B2 (en) | 2009-04-16 | 2014-02-04 | Isis Innovation Limited | Hydroxybutyrate ester and medical use thereof |
| AU2010207597A1 (en) | 2009-01-24 | 2011-08-18 | Phytopharm Plc | Treatment of neurotrophic factor mediated disorders |
| WO2011085271A2 (en) * | 2010-01-08 | 2011-07-14 | Isis Pharmaceuticals, Inc. | Modulation of angiopoietin-like 3 expression |
| GB201002983D0 (en) * | 2010-02-22 | 2010-04-07 | Tdeltas Ltd | Nutritinal composition |
| BR112013001422A2 (pt) | 2010-07-20 | 2019-09-24 | Phytopharm Plc | metodo para tratar ou previnir disturbios induzidos por l-dopa, agonista dopamina e/ou acentuador de dopamina em um individuo que necessita dos mesmos, agente, composição, uso de ou mais agentes e metodo para tratar a doença de parkinson |
| WO2014071389A1 (en) | 2012-11-05 | 2014-05-08 | Veech Richard L | Ketone bodies to protect tissues from damage by ionizing radiation |
| GB201304467D0 (en) | 2013-03-12 | 2013-04-24 | Tdeltas Ltd | Compound for use in protecting skin |
| GB2515603B (en) | 2013-03-14 | 2015-10-14 | Isis Innovation | Process for producing (R)-3-Hydroxybutyl (R)-3-Hydroxybutyrate |
| BR112015024186B1 (pt) | 2013-03-19 | 2023-05-09 | University Of South Florida | Composições e métodos para produção de cetose de elevação e manutenção |
| US10973792B2 (en) | 2019-02-13 | 2021-04-13 | Axcess Global Sciences, Llc | Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use |
| US10292952B2 (en) | 2016-03-11 | 2019-05-21 | Axcess Global Sciences, Llc | Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis |
| US10736861B2 (en) | 2016-03-11 | 2020-08-11 | Axcess Global Sciences, Llc | Mixed salt compositions for producing elevated and sustained ketosis |
| US10973786B2 (en) | 2016-03-11 | 2021-04-13 | Axcess Global Sciences, Llc | R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions |
| US10596130B2 (en) | 2017-12-19 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use |
| US11103470B2 (en) | 2017-11-22 | 2021-08-31 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US11185518B2 (en) | 2017-12-19 | 2021-11-30 | Axcess Global Sciences, Llc | S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer |
| US11241403B2 (en) | 2016-03-11 | 2022-02-08 | Axcess Global Sciences, Llc | Beta-hydroxybutyrate mixed salt compositions and methods of use |
| US10596131B2 (en) | 2017-11-22 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US10596129B2 (en) | 2017-11-22 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US10245243B1 (en) | 2017-12-19 | 2019-04-02 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use |
| US10245242B1 (en) | 2017-11-22 | 2019-04-02 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US12533346B2 (en) | 2016-04-19 | 2026-01-27 | Axcess Global Sciences, Llc | Administration of berberine metabolites |
| US12599579B2 (en) | 2016-04-19 | 2026-04-14 | Axcess Global Sciences, Llc | Compositions and compounds containing ketone bodies and/or ketone body precursors and one or more amino acids |
| US11202769B2 (en) | 2017-11-22 | 2021-12-21 | Axcess Global Sciences, Llc | Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function |
| US12109182B2 (en) | 2016-04-19 | 2024-10-08 | Axcess Global Sciences, Llc | Administration of R-beta-hydroxybutyrate and related compounds in humans |
| US10925843B2 (en) | 2018-04-18 | 2021-02-23 | Axcess Global Sciences, Llc | Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate |
| US11026929B2 (en) | 2016-04-19 | 2021-06-08 | Keto Patent Group, Inc. | Administration of berberine metabolites |
| US11944598B2 (en) | 2017-12-19 | 2024-04-02 | Axcess Global Sciences, Llc | Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer |
| US12496283B2 (en) | 2016-04-19 | 2025-12-16 | Axcess Global Sciences, Llc | Administration of R-beta-hydroxybutyrate and related compounds in humans |
| US12521378B2 (en) | 2016-04-19 | 2026-01-13 | Axcess Global Sciences, Llc | Administration of R-beta-hydroxybutyrate salt blend and related compounds in humans |
| US12622889B2 (en) | 2016-04-19 | 2026-05-12 | Axcess Global Sciences, Llc | S-β-hydroxybutyrate esters for improving metabolic function |
| US11806324B2 (en) | 2018-04-18 | 2023-11-07 | Axcess Global Sciences, Llc | Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies |
| US20230346721A1 (en) | 2018-04-18 | 2023-11-02 | Axcess Global Sciences, Llc | Beta-hydroxybutyric acid compositions and methods for delivery of ketone bodies |
| US12329734B2 (en) | 2017-12-19 | 2025-06-17 | Axcess Global Sciences, Llc | Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow |
| US11760963B2 (en) | 2017-08-23 | 2023-09-19 | KetoneAid Inc. | Ketogenic beer and alcoholic beverage mixture containing non-racemic ethyl 3-hydroxybutyrate and/or 1,3 butanediol |
| US20180057846A1 (en) | 2016-08-30 | 2018-03-01 | KetoneAid Inc. | Partially buffered free acid and/or ketone blend for rapid onset ketosis and metabolic therapy |
| US10307398B2 (en) | 2016-09-20 | 2019-06-04 | Regents Of The University Of Minnesota | Resuscitation composition and methods of making and using |
| WO2018115158A1 (en) | 2016-12-21 | 2018-06-28 | Universitäts-Kinderspital Beider Basel | Migraine prevention and treatment |
| MX390420B (es) * | 2016-12-23 | 2025-03-20 | Univ Leuven Kath | 3-hidroxibutirato solo o en combinación para su uso en el tratamiento de cuidados intensivos. |
| US10376528B2 (en) | 2017-03-10 | 2019-08-13 | Tecton Group, Llc | Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor |
| US12171735B2 (en) | 2017-04-19 | 2024-12-24 | Axcess Global Sciences, Llc | Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans |
| US12090129B2 (en) | 2017-11-22 | 2024-09-17 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| GB2572185A (en) * | 2018-03-21 | 2019-09-25 | Chain Biotechnology Ltd | Pharmaceutical compositions |
| US11419836B2 (en) | 2019-02-13 | 2022-08-23 | Axcess Global Sciences, Llc | Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions |
| US11129802B2 (en) | 2018-08-27 | 2021-09-28 | Axcess Global Sciences, Llc | Compositions and methods for delivering cannabidiol and ketone bodies |
| US11241401B2 (en) | 2020-02-06 | 2022-02-08 | Axcess Global Sciences, Llc | Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions |
| US10980772B2 (en) | 2018-08-27 | 2021-04-20 | Axcess Global Sciences, Llc | Compositions and methods for delivering tetrahydrocannabinol and ketone bodies |
| US10512615B1 (en) | 2018-08-27 | 2019-12-24 | Axcess Global Sciences, Llc | Compositions and methods for delivering cannabidiol and ketone bodies |
| US12472200B2 (en) | 2019-05-15 | 2025-11-18 | Axcess Global Sciences, Llc | Autobiotic compositions and method for promoting healthy gut microbiome |
| US11950616B2 (en) | 2019-06-21 | 2024-04-09 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
| US11969430B1 (en) | 2023-03-10 | 2024-04-30 | Axcess Global Sciences, Llc | Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance |
| US12167993B2 (en) | 2019-06-21 | 2024-12-17 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
| US11033553B2 (en) | 2019-06-21 | 2021-06-15 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
| IT201900022854A1 (it) * | 2019-12-03 | 2021-06-03 | Dr Schaer S P A | Formulazione alimentare e prodotto alimentare da forno per la gestione della dieta chetogenica |
| WO2021195477A1 (en) | 2020-03-27 | 2021-09-30 | Ketoneaid, Inc. | Ketone ester as a therapeutic treatment of covid-19, long covid, and related viral infections |
| US12186297B2 (en) | 2020-08-26 | 2025-01-07 | Axcess Global Sciences, Llc | Compositions and methods for increasing lean-to-fat mass ratio |
| US20250275986A1 (en) | 2021-07-17 | 2025-09-04 | Ketoswiss Ag | Combination of a ketone body or ketogenic compound with an analgesic or antioxidant |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5286842A (en) * | 1991-07-01 | 1994-02-15 | Mitsubishi Kasei Corporation | Process for producing a biodegradable polymer |
| RU2064793C1 (ru) * | 1992-03-31 | 1996-08-10 | Игорь Васильевич Комиссаров | Стресспротективное средство, обладающее антиамнестическим, антигипоксическим, противотревожным и противошоковым действием |
| JP2885261B2 (ja) * | 1993-05-17 | 1999-04-19 | 三菱瓦斯化学株式会社 | ３−ヒドロキシ酪酸のオリゴマー及びその塩からなる輸液製剤 |
| JP4598203B2 (ja) | 1995-12-01 | 2010-12-15 | ビーティージー・インターナショナル・リミテッド | 脳機能改善剤 |
| CN1315473C (zh) * | 1997-03-17 | 2007-05-16 | 英国技术集团国际有限公司 | 治疗组合物 |
| US6323237B1 (en) * | 1997-03-17 | 2001-11-27 | Btg International Limited | Therapeutic compositions |
| DE69903792T2 (de) * | 1998-01-07 | 2003-08-14 | Metabolix, Inc. | Tierfutterzusammensetzungen |
| CA2338090C (en) * | 1998-07-22 | 2009-07-14 | Metabolix, Inc. | Nutritional and therapeutic compositions of 3-hydroxyacids for increasing blood ketone bodies |
-
1999
- 1999-09-15 CA CA002339941A patent/CA2339941A1/en not_active Abandoned
- 1999-09-15 JP JP2000569800A patent/JP2002524506A/ja active Pending
- 1999-09-15 DK DK99946906T patent/DK1123094T3/da active
- 1999-09-15 NZ NZ509739A patent/NZ509739A/en not_active IP Right Cessation
- 1999-09-15 EP EP99946906A patent/EP1123094B1/de not_active Expired - Lifetime
- 1999-09-15 DE DE69935799T patent/DE69935799T2/de not_active Expired - Lifetime
- 1999-09-15 BR BR9913680-5A patent/BR9913680A/pt not_active Application Discontinuation
- 1999-09-15 KR KR1020017003343A patent/KR100805490B1/ko not_active Expired - Fee Related
- 1999-09-15 ES ES99946906T patent/ES2283133T3/es not_active Expired - Lifetime
- 1999-09-15 CN CNB998108375A patent/CN1273129C/zh not_active Expired - Fee Related
- 1999-09-15 WO PCT/US1999/021015 patent/WO2000015216A1/en not_active Ceased
- 1999-09-15 AU AU59212/99A patent/AU767238B2/en not_active Ceased
- 1999-09-15 AT AT99946906T patent/ATE359069T1/de active
- 1999-09-15 PT PT99946906T patent/PT1123094E/pt unknown
- 1999-09-15 RU RU2001110097/15A patent/RU2242227C2/ru not_active IP Right Cessation
-
2001
- 2001-02-14 ZA ZA200101260A patent/ZA200101260B/en unknown
- 2001-03-06 US US09/799,124 patent/US20010014696A1/en not_active Abandoned
-
2003
- 2003-12-15 US US10/734,586 patent/US7351736B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| KR20010079830A (ko) | 2001-08-22 |
| DK1123094T3 (da) | 2007-08-20 |
| WO2000015216A1 (en) | 2000-03-23 |
| HK1035665A1 (en) | 2001-12-07 |
| CN1316902A (zh) | 2001-10-10 |
| EP1123094A4 (de) | 2001-10-04 |
| KR100805490B1 (ko) | 2008-02-20 |
| BR9913680A (pt) | 2001-06-05 |
| ES2283133T3 (es) | 2007-10-16 |
| ZA200101260B (en) | 2001-08-16 |
| EP1123094B1 (de) | 2007-04-11 |
| US7351736B2 (en) | 2008-04-01 |
| RU2242227C2 (ru) | 2004-12-20 |
| NZ509739A (en) | 2003-10-31 |
| US20010014696A1 (en) | 2001-08-16 |
| JP2002524506A (ja) | 2002-08-06 |
| DE69935799D1 (de) | 2007-05-24 |
| DE69935799T2 (de) | 2007-12-27 |
| EP1123094A1 (de) | 2001-08-16 |
| US20040171671A1 (en) | 2004-09-02 |
| CA2339941A1 (en) | 2000-03-23 |
| AU767238B2 (en) | 2003-11-06 |
| AU5921299A (en) | 2000-04-03 |
| PT1123094E (pt) | 2007-06-28 |
| CN1273129C (zh) | 2006-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69935799D1 (de) | Therapeutische zusammenstellungen | |
| DE69713526D1 (de) | Lösliche prodrugs von paclitaxel | |
| MX9203543A (es) | Medicamento. | |
| KR930702022A (ko) | 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법 | |
| RU94045155A (ru) | Способы ингибирования болезни альцгеймера | |
| ATE410506T1 (de) | Behandlung der pompeschen krankheit | |
| CA2223403A1 (en) | Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) n-¬(aminoiminomethyl)phenylalkyl|-azaheterocyclylamide compounds | |
| NO20004311L (no) | Farmasøytisk sammensetning av topiramat | |
| MY130157A (en) | Method of use for inhibiting bone loss and lowering serum cholesterol | |
| ATE262909T1 (de) | Intravenöse alendronatformulierungen | |
| WO2001036510A3 (en) | Use of poly(diallylamine) polymers | |
| RU2001110097A (ru) | Терапевтические композиции (ii) | |
| PT998287E (pt) | Utilizacao de levobupivacaina | |
| IL124977A0 (en) | Oral administration of effective amounts of forms of hyaluronic acid | |
| KR900015718A (ko) | 골관절염 치료제 | |
| MXPA02003495A (es) | Derivados de piridinio para el manejo de complicaciones vasculares diabeticas y relacionadas con la edad, proceso para su preparacion, y usos terapeuticos de los mismos. | |
| SE8500996D0 (sv) | Method of treatment | |
| DE3688787D1 (de) | Herstellung eines arzneimittels gegen arthritis und rheumatismus. | |
| Rail et al. | Improvement in nerve condition after plasma exchange for Guillain-Barré syndrome | |
| ATE207353T1 (de) | Verwendung von benzydamin zur behandlung von krankheitszuständen, die durch tnf verursacht werden | |
| AU1645897A (en) | Benzopyran derivative and use of said benzopyran derivative for treating heart disease | |
| SU944583A1 (ru) | Способ реабилитации травматических поражений мышц | |
| CN1045534C (zh) | 去疣组合物 | |
| UA10301A (uk) | Спосіб лікуваhhя раку шлуhку | |
| DK601788A (da) | Anvendelse af antibiotikaene ll-e19020alfa og ll-e19020beta til behandling af visse fjerkraesygdomme |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1123094 Country of ref document: EP |